Viral Hepatitis C Clinical Trial
Official title:
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
To assess the safety and tolerability of the use of telaprevir in the setting of
post-exposure prophylaxis among HCW exposed to HCV genotype 1 or genotype 2.
To assess the election rate of postexposure prophylaxis for HCV-related occupational
exposures in HCW.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - MGH or BWH health care workers with exposure through needlestick injury with hollow-bore needles to source patients who are anti-HCV (+) and HCV RNA (+) - HCW is anti-HCV Ab negative. HCW exposed through needlestick injury with hollow-bore needles to source patients who are anti-HCV (+) and HCV RNA (-), regardless of the RIBA result, will not be eligible for the study. In addition, efforts will be made to identify the source patient's genotype, and if the genotype is unknown, then genotype testing will be performed. If the genotype is 2 or 3, then the HCW exposed to the source patient will not be eligible for the study. - HCW will be eligible if exposed to a source patient who has a genotype 1, or if the genotype of the source patient is unknown or unable to be ascertained Exclusion Criteria: - Exposure to patient with known HCV genotype 2 or 3 - HCV Ab positive - HCV Ab negative and HCV RNA > 1000 IU/ml - Active malignancy - Other condition in the opinion of the investigators or occupational health that makes telaprevir contraindicated in HCW - Subjects with pre-existing end stage renal impairment or severe hepatic impairment (Child Pugh B or C), and anemia (starting hemoglobin 10 or less) will be excluded. - Pregnant women will be excluded from the study. All female participants with reproductive potential will undergo a pregnancy test (specifically qualitative urine human chorionic gonadotropin), and those who test positive will not be eligible for study inclusion. Women whom are not pregnant and elect to enroll in the study will be advised that hormonal contraceptives may not be reliable during the study period and for up to two weeks following cessation of the study drug. During this time, female patients of childbearing potential should use two non-hormonal methods of effective birth control, examples of which include a male condom with spermicidal jelly OR female condom with spermicidal jelly (a combination of a male condom and a female condom is not suitable), a diaphragm with spermicidal jelly, a cervical cap with spermicidal jelly, or an intrauterine device (IUD). |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | We seek to monitor the safety and tolerability of telaprevir, specifically with respect to the reported adverse effects of rash, pruritus, nausea, diarrhea, vomiting, anal or rectal discomfort (including hemorrhoids), dysgeusia, and fatigue. Furthermore, we will assess the incidence of anemia in the study population at weeks 1, 2, and 4. | One year | Yes |
Secondary | Election rate of study drug | During the study period, we will measure the proportion of health care workers who elect to take telaprevir for HCV post-exposure prophylaxis among the total number of HCW eligible to receive the study drug. We will also record the reasons why eligible HCW declined to participate in the study, if disclosed to the study staff. | One year | No |
Secondary | Rate of HCV infection | Although this trial is not designed nor powered to study the efficacy of telaprevir for post-exposure prophylaxis, it will be important to measure the breakthrough rate of HCV in patients who elected treatment for 4 weeks and to calculate the rate of HCV among those who elect to not take telaprevir. The trial will be performed according to an intention-to-treat analysis. | One year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04470271 -
Re-linkage to Care of Patients With Hepatitis C
|
||
Completed |
NCT03537196 -
DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)
|
Phase 4 | |
Recruiting |
NCT05751889 -
Serious Game Interventions to Reduce Viral Hepatitis C Among PLWH-MSM
|
N/A | |
Completed |
NCT03566966 -
Autoantibodies and Direct-acting Antivirals
|
||
Completed |
NCT04047680 -
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
|
||
Not yet recruiting |
NCT04690972 -
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
|
||
Active, not recruiting |
NCT01953458 -
Therapeutic Option for Hepatitis B and C: a French Cohort
|
||
Completed |
NCT02125500 -
Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
|
Phase 2 |